Latest news articles

Added 7 months ago Drug news

Phase II/III Act.In.Sarc trial of NBTXR 3 in Soft Tissue Sarcomas published in Lancet Oncology

Nanobiotix announced that the previously reported results from the Phase II/III Act.In.Sarc trial evaluating NBTXR 3 in patients with advanced...

Added 10 months ago Drug news

Phase III TAPPAS trial of TRC 105 + Votrient terminated in sarcoma

TRACON Pharmaceuticals announced that its Phase III TAPPAS trial evaluating TRC 105 (carotuximab) in combination with Votrient (pazopanib) in patients...

Added 1 year ago Drug news

Phase III ANNOUNCE study of Lartruvo fails to meet endpoint in soft tissue sarcoma.- Eli Lilly

Eli Lilly reported that the results of ANNOUNCE, the Phase III study of Lartruvo (olaratumab), in combination with doxorubicin in...

Search all news articles for Cancer; other and unspecified primary
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

CDK 4/6 inhibitors in metastatic breast cancer

CDK 4/6 inhibitors in metastatic breast cancer

The CDK 4/6 Inhibitors in Metastatic Breast Cancer Learning Zone provides insights and information for metastatic breast cancer (mBC) and CDK 4/6 signalling. This includes the burden and pathophysiology of the disease, the role of CDK 4/6 in cell proliferation and an overview of the CDK 4/6 inhibitors that have been approved for the management of mBC.

Load more

Guidelines

Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines

Anaemia and iron deficiency are frequent complications in patients with solid tumours or haematological malignancies, particularly in patients treated with chemotherapeutic agents.

Added 1 year ago

European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas

The present European Society of Endocrinology (ESE) guideline aims to provide clinical guidance on diagnosis, treatment and follow-up in aggressive pituitary tumours and carcinomas.

Added 1 year ago

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Immunotherapy is an essential component of cancer care and expands the treatment possibilities for patients. Immune checkpoint inhibitors are among the most promising drugs but are associated with toxicities.

Added 2 years ago

Search all guidelines for Cancer; other and unspecified primary
 

Journal articles

Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes.

Introduction: To evaluate the possibility that switching from reference biologic medicines to biosimilars could lead to altered clinical outcomes, including enhanced immunogenicity, compromised safety, or diminished efficacy...

Added 1 month ago

A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo.

Nanoscale robots have potential as intelligent drug delivery systems that respond to molecular triggers. Using DNA origami we constructed an autonomous DNA robot programmed to transport payloads and present them specifically in tumors.

Added 2 years ago

Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis.

The development of FLT3-targeted inhibitors represents an important paradigm shift in the management of patients with highly aggressive fms-like tyrosine kinase 3-mutated (FLT3-mut) acute myeloid leukemia (AML).

Added 2 years ago

Search all journal articles for Cancer; other and unspecified primary
 

Clinical trials

A Study of Zelboraf (Vemurafenib) in Patients With BRAF V600 Mutation-Positive Cancers

This open-label, multi-center study will assess the efficacy and safety of Zelboraf (vemurafenib) in patients with BRAF V600 mutation-positive cancers...

Added 2 years ago

Search all clinical trials for Cancer; other and unspecified primary
 

CME

Carcinoma of unknown primary origin: diagnosis and management: putting NICE guidelines into practice

Accrediting body
Union of European Medical Specialists (via European Accreditation Council for CME)
Credits available
1
Registration required
1
Subscription fee
90
Search all CME for Cancer; other and unspecified primary